2016 ; 26(11):
|Author||Yun-Gyeong Lee, Jung-Ho Park, Eun-Seok Jeon, Jin-Hee Kim, Byung-Kwan Lim|
|Affiliation||Department of Biomedical Science, Jungwon University, Goesan 28024, Republic of Korea|
|Title||Fructus Amomi Cardamomi Extract Inhibits Coxsackievirus-B3 Induced Myocarditis in a Murine Myocarditis Model|
J. Microbiol. Biotechnol.2016 ; 26(11):
|Abstract||Coxsackievirus B3 (CVB3) is the main cause of acute myocarditis and dilated cardiomyopathy. Plant extract is considered as useful materials to develop new antiviral drug. We select the candidate plant extract, which showed anti-inflammatory effect previously. We examined the antiviral effects by using a HeLa cell survival assay. Among these extracts, we chose the Amomi Cardamomi (Amomi) extract, which showed strong antiviral effect and preserved cell survival in CVB3 infection. We investigated the mechanisms underlying the ability of Amomi extract to inhibit CVB3 infection and replication. HeLa cells infected by CVB3 with or without Amomi extract. Erk and Akt activity, and its correlation with virus replication was observed. Live virus titer in cell supernatants and viral positive- and negative-strand RNA amplification were measured. Amomi extract significantly increased HeLa cell survival in different concentrations (100–10㎍/㎖). Production of the viral capsid protein VP1 (76%) and viral protease 2A–induced eIF4G1 cleavage (70%) were significantly decreased in Amomi extract (100㎍/㎖) treated cells. The levels of positive- (20%) and negative-strand (80%) RNA were dramatically decreased compared to control, as revealed by reverse transcription–PCR. In addition, Amomi extract improved mice survival (51% vs 26%) and dramatically reduced heart inflammation in CVB3-induced myocarditis mouse model. These results suggested that Amomi extract was significantly inhibited Enterovirus replication and myocarditis damage. Amomi may be develop therapeutic drug for Enterovirus.|
|Keywords||Coxsackievirus B3, Myocarditis, Plant extract, Antiviral effect, Enterovirus|
Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU. 2000. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J. Biol. Chem. 275: 11191-11197.
Chen TC, Weng KF, Chang SC, Lin JY, Huang PN, Shih SR. 2008. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 62: 1169-1173.
Choi HG, Je IG, Kim GJ, Choi H, Kim SH, Kim JA, Lee KS. 2015. Anti-allergic inflammatory activities of compounds of amomi fructus. Nat. Prod. Commun. 10: 631-632.
Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, Zhang J, McManus BM. 2004. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J. Virol. 78: 4289-4298.
Feldman AM, McNamara D. 2000. Myocarditis. N. Engl. J. Med. 343: 1388-1398.
Herskowitz A, Beisel KW, Wolfgram LJ, Rose NR. 1985. Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains. Hum. Pathol. 16: 671-673.
Kearney MT, Cotton JM, Richardson PJ, Shah AM. 2001. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad. Med. J. 77: 4-10.
Kim JM, Lim BK, Ho SH, Yun SH, Shin JO, Park EM, et al. 2006. TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. Biochem. Biophys. Res. Commun. 344: 765-771.
Knowlton KU, Badorff C. 1999. The immune system in viral myocarditis: maintaining the balance. Circ. Res. 85: 559-561.
Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70: 7811-7818.
Kumar S, Pandey AK. 2013. Chemistry and biological activities of flavonoids: an overview. Scientific World Journal 2013: 162750.
Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS, et al. 2002. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105: 1278-1281.
Lim BK, Choi JH, Nam JH, Gil CO, Shin JO, Yun SH, et al. 2006. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc. Res. 71:517-526.
Lim BK, Kim JH. 2014. ORI2 inhibits coxsackievirus replication and myocardial inflammation in experimental murine myocarditis. Biol. Pharm. Bull. 37: 1650-1654.
Lim BK, Nam JH, Gil CO, Yun SH, Choi JH, Kim DK, Jeon ES. 2005. Coxsackievirus B3 replication is related to activation of the late extracellular signal-regulated kinase (ERK) signal. Virus Res. 113: 153-157.
Lim BK, Xiong D, Dorner A, Youn TJ, Yung A, Liu TI, et al. 2008. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J. Clin. Invest. 118: 2758-2770.
Lim BK, Yun SH, Gil CO, Ju ES, Choi JO, Kim DK, Jeon ES. 2012. Foreign gene transfer to cardiomyocyte using a replication-defective recombinant coxsackievirus B3 without cytotoxicity. Intervirology 55: 201-209.
Lim BK, Yun SH, Ju ES, Gil CO, Kim DK, Jeon ES. 2012. Role of the myristoylation site in expressing exogenous functional proteins in coxsackieviral vector. Biosci. Biotechnol. Biochem. 76: 1173-1176.
Liu P, Martino T, Opavsky MA, Penninger J. 1996. Viral myocarditis: balance between viral infection and immune response. Can. J. Cardiol. 12: 935-943.
Martino TA, Liu P, Sole MJ. 1994. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74: 182188.
Schnitzler P, Neuner A, Nolkemper S, Zundel C, Nowack H, Sensch KH, Reichling J. 2010. Antiviral activity and mode of action of propolis extracts and selected compounds. Phytother. Res. 24 Suppl 1: S20-S28.
Song JH, Kwon BE, Jang H, Kang H, Cho S, Park K, et al. 2015. Antiviral activity of chrysin derivatives against coxsackievirus B3 in vitro and in vivo. Biomol. Ther. (Seoul) 23: 465-470.
Sun F, Li Y, Jia T, Ling Y, Liang L, Liu G, et al. 2012. Differential expression of coxsackievirus and adenovirus receptor on alveolar epithelial cells between fetal and adult mice determines their different susceptibility to coxsackievirus B infection. Arch. Virol. 157: 1101-1111.
Wang SM, Liu CC. 2014. Update of enterovirus 71 infection:epidemiology, pathogenesis and vaccine. Expert Rev. Anti Infect. Ther. 12: 447-456.
Wong J, Zhang J, Yanagawa B, Luo Z, Yang X, Chang J, et al. 2012. Cleavage of serum response factor mediated by enteroviral protease 2A contributes to impaired cardiac function. Cell Res. 22: 360-371.
Woodruff JF. 1980. Viral myocarditis. A review. Am. J. Pathol. 101: 425-484.
Xiong D, Lee GH, Badorff C, Dorner A, Lee S, Wolf P, Knowlton KU. 2002. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat. Med. 8: 872-877.
Xiong D, Yajima T, Lim BK, Stenbit A, Dublin A, Dalton ND, et al. 2007. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115: 94-102.
Yu J, Sun L, Zhou L, Luo X, Guo J, Liu C, Cong P. 1997. [Chemical constituents of fructus Amomi]. Zhongguo Zhong Yao Za Zhi 22: 231-232, 255.
Yun SH, Lee WG, Kim YC, Ju ES, Lim BK, Choi JO, et al. 2012. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 205: 491-497.